Abstract
Blood and urine acylcarnitine profiles are commonly used to diagnose long-chain fatty acid oxidation disorders (FAOD: i.e., long-chain hydroxy-acyl-CoA dehydrogenase [LCHAD] and carnitine palmitoyltransferase 2 [CPT2] deficiency), but the global metabolic impact of long-chain FAOD has not been reported. We utilized untargeted metabolomics to characterize plasma metabolites in 12 overnight-fasted individuals with FAOD (10 LCHAD, two CPT2) and 11 healthy age-, sex-, and body mass index (BMI)-matched controls, with the caveat that individuals with FAOD consume a low-fat diet supplemented with medium-chain triglycerides (MCT) while matched controls consume a typical American diet. In plasma 832 metabolites were identified, and partial least squared-discriminant analysis (PLS-DA) identified 114 non-acylcarnitine variables that discriminated FAOD subjects and controls. FAOD individuals had significantly higher triglycerides and lower specific phosphatidylethanolamines, ceramides, and sphingomyelins. Differences in phosphatidylcholines were also found but the directionality differed by metabolite species. Further, there were few differences in non-lipid metabolites, indicating the metabolic impact of FAOD specifically on lipid pathways. This analysis provides evidence that LCHAD/CPT2 deficiency significantly alters complex lipid pathway flux. This metabolic signature may provide new clinical tools capable of confirming or diagnosing FAOD, even in subjects with a mild phenotype, and may provide clues regarding the biochemical and metabolic impact of FAOD that is relevant to the etiology of FAOD symptoms.
Similar content being viewed by others
References
American College of Medical Genetics Newborn Screening Expert Group (2006) Newborn screening: toward a uniform screening panel and system. Genet Med 8(1):1s–252s
Bach AC, Babayan VK (1982) Medium-chain triglycerides: an update. Am J Clin Nutr 36(5):950–962
Bakermans AJ et al (2013) Myocardial energy shortage and unmet anaplerotic needs in the fasted long-chain acyl-CoA dehydrogenase knockout mouse. Cardiovasc Res 100(3):441–449
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B Method 57(1):289–300
Cajka T, Fiehn O (2014) Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry. TrAC Trend Anal Chem 61:192–206
Cole LK, Vance JE, Vance DE (2012) Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim Biophys Acta (BBA) Molecul Cell Biol Lipid 1821(5):754–761
Development Core Team (2005) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Domingues MRM, Reis A, Domingues P (2008) Mass spectrometry analysis of oxidized phospholipids. Chem Phys Lipids 156(1–2):1–12
Fiehn O, Kind T (2007) Metabolite profiling in blood plasma. Methods Mol Biol 358:3–17
Fiehn O, Wohlgemuth G, Scholz M (2005) Setup and annotation of metabolomic experiments by integrating biological and mass spectrometric metadata. In: Ludäscher B, Raschid L (eds) Data integration in the life sciences. Springer, Berlin, pp 224–239
Gault CR, Obeid LM, Hannun YA (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688:1–23
Gillingham MB et al (2013) Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder. Am J Physiol Endocrinol Metab 305(10):E1299–E1308
Houten SM et al (2013) Impaired amino acid metabolism contributes to fasting-induced hypoglycemia in fatty acid oxidation defects. Hum Mol Genet 22(25):5249–5261
Jacobs RL et al (2008) Hepatic CTP:phosphocholine cytidylyltransferase-alpha is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J Biol Chem 283(4):2147–2155
Jenkins B, West JA, Koulman A (2015) A review of odd-chain fatty acid metabolism and the role of pentadecanoic acid (c15:0) and heptadecanoic acid (c17:0) in health and disease. Molecules 20(2):2425–2444
Kim H, Golub GH, Park H (2005) Missing value estimation for DNA microarray gene expression data: local least squares imputation. Bioinformatics 21(2):187–198
Kind T et al (2013) LipidBlast in silico tandem mass spectrometry database for lipid identification. Nat Methods 10(8):755–758
Kontush A, Chapman MJ (2010) Lipidomics as a tool for the study of lipoprotein metabolism. Curr Atheroscler Rep 12(3):194–201
Lahti L et al (2013) Associations between the human intestinal microbiota, Lactobacillus rhamnosus GG and serum lipids indicated by integrated analysis of high-throughput profiling data. Peer J 1:e32
Matyash V et al (2008) Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res 49(5):1137–1146
McCoin CS, Knotts TA, Adams SH (2015) Acylcarnitines: old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol 11(10):617–625
Mehmood T et al (2012) A review of variable selection methods in partial least squares regression. Chemomet Intell Lab Syst 118:62–69
Mevik B-H, Wehrens R (2007) The pls package: principal component and partial least squares regression in R. J Stat Soft 18(2):1–24
Najdekr L et al (2015) Oxidized phosphatidylcholines suggest oxidative stress in patients with medium-chain acyl-CoA dehydrogenase deficiency. Talanta 139:62–66
Orngreen MC et al (2005) Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol 57(1):60–66
Piccolo BD et al (2015) Whey protein supplementation does not alter plasma branched-chained amino acid profiles but results in unique metabolomics patterns in obese women enrolled in an 8-week weight loss trial. J Nutr doi: 10.3945/jn.114.203943
Rinaldo P, Matern D, Bennett MJ (2002) Fatty acid oxidation disorders. Annu Rev Physiol 64:477–502
Rinaldo P, Cowan TM, Matern D (2008) Acylcarnitine profile analysis. Genet Med 10(2):151–156
Roe CR et al (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110(2):259–269
Scholz M, Fiehn O (2007) SetupX—a public study design database for metabolomic projects. Pac Symp Biocomput 2007:169–80
Smith EH, Matern D (2010) Acylcarnitine analysis by tandem mass spectrometry. Curr Protoc Hum Genet Chapter 17:p. Unit 17.8.1–20
Troyanskaya O et al (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17(6):520–525
Tucci S et al (2014) Development and pathomechanisms of cardiomyopathy in very long-chain acyl-CoA dehydrogenase deficient (VLCAD−/−) mice. Bioch Biophys Acta (BBA) Molecul Bas Dis 1842(5):677–685
Wanders RJ et al (1999) Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis 22(4):442–487
Watson MS et al (2006) Main Report. Genet Med 8:12S–252S
Wilcken B et al (2003) Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New England J Med 348(23):2304–2312
Wold S, Sjöström M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemomet Intell Lab Syst 58(2):109–130
Acknowledgments
The authors would like to thank Dr. Oliver Fiehn of the West Coast Metabolomics Center at UC Davis for his support of the metabolomics and lipidomics analysis. The West Coast Metabolomics Center is supported by NIH Grant U24 DK097154. Additionally, the authors would like to thank Dr. John Newman of the USDA Western Human Nutrition Research Center for his support in interpretation of the lipidomics analysis as well as Dr. Paul Coen of the Translational Research Institute for Metabolism and Diabetes for his insightful comments and review of this manuscript. The genesis of this project emerged from results from grants awarded by the NIH-NIDDK (R01DK078328 and R01DK078328-02S1, to S.H.A. and K01DK071869, to M.G.) and USDA-ARS intramural Project 5306-51530-019-00, and the studies supported by a UC Davis Clinical and Translational Science Center (CTSC) Pilot Award (to S.H.A., J.V., M.G.) funded by the NIH National Center for Advancing Translational Sciences, through grant number UL1TR000002. This project was also supported by a NIH T32 pre-doctoral training award (to C.S.M.), funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1 TR000002 and linked award TL1 TR000133. J.V. was supported in part by R01-DK78755. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Informed consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Written informed consent was obtained from all patients or legal guardians prior to inclusion in the study.
Additional information
Communicated by: Ronald JA Wanders
Colin S. McCoin and Brian D. Piccolo contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplemental Table 1
Complete data set containing quantifier ion peak heights (QIPH) for untargeted plasma metabolomics and lipidomics from healthy control subjects (n = 11) and individuals with FAOD diagnosed with LCHAD (n = 10) or CPT2 (n = 2) (XLSX 428 kb)
Supplemental Table 2
Bootstrapped variable importance in projection (VIP) statistics from partial least squared-discriminant analyses (PLS-DA) of Model 1 and Model 2 from plasma of healthy control (n = 11) and FAOD (n = 12) individuals with FAOD (XLSX 39.3 kb)
Supplemental Table 3
Diagnostic and supplementation information for FAOD subjects (XLSX 14 kb)
Supplemental Table 4
Plasma acylcarnitine analysis performed on 10 h fasted FAOD and healthy control subjects (XLSX 14 kb)
Rights and permissions
About this article
Cite this article
McCoin, C.S., Piccolo, B.D., Knotts, T.A. et al. Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation. J Inherit Metab Dis 39, 399–408 (2016). https://doi.org/10.1007/s10545-016-9915-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-016-9915-3